A phase I trial in which patients with recurrent glioma received DCs pulsed with WT1 also reported no serious adverse events, and 6 of 10 patients showed a two-fold or greater increase in WT1-specific cytotoxic T lymphocytes by tetramer analysis (73). Here, WT1 is linked to glioma.